David M. Stack - Jun 14, 2023 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
CEO and Chairman, Director
Signature
/s/ Kristen Williams, Attorney-in-Fact
Stock symbol
PCRX
Transactions as of
Jun 14, 2023
Transactions value $
$0
Form type
4
Date filed
6/16/2023, 05:40 PM
Previous filing
Jun 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Award $0 +32.7K +21.26% $0.00 186K Jun 14, 2023 Direct F1
holding PCRX Common Stock 97.3K Jun 14, 2023 By Three Colleens Investment, LLC F2
holding PCRX Common Stock 18.6K Jun 14, 2023 By Stack Schroon Mohawk FLP F2
holding PCRX Common Stock 315 Jun 14, 2023 LCK Investment LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Award $0 +245K $0.00 245K Jun 14, 2023 Common Stock 245K $38.74 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2024, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2 Mr. Stack and his wife are the owners of each of Three Colleens Investment, LLC and LCK Investment LLC. Mr. Stack is the general partner of Stack Schroon Mohawk FLP.
F3 The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.